ClinicalEndocrinologyFDA News. Advertisement. The FDA has set Prescription Drug User Fee (PDUFA) target action dates of December 29 and December 30 …
FDA Approves Eylea Biosimilar Aflibercept-mrbb for Serious Retinal Diseases – HCPLive
Share This Story, Choose Your Platform!
About the Author:
Leave A Comment